Table 1 Single dose acute and delayed study design
From: Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
Group | Mice/group | Sex | Compound | Collecteda at day 2 | Collecteda at day 14 |
|---|---|---|---|---|---|
Untreated control | 4 | F | None | 2 | 2 |
Untreated control | 4 | M | None | 2 | 2 |
Vehicle Control | 10 | F | Saline | 5 | 5 |
Vehicle control | 10 | M | Saline | 5 | 5 |
2 nmoles IRDye800CW-nimotuzumab | 10 | F | 15 mg/kg IRDye800CW-nimotuzumab | 5 | 5 |
2 nmoles IRDye800CW-nimotuzumab | 10 | M | 15 mg/kg IRDye800CW-nimotuzumab | 5 | 5 |